Loading organizations...
§ Private Profile · San Francisco, CA, USA
Quanta Therapeutics is a technology company.
Quanta Therapeutics has raised $111.0M across 2 funding rounds.
Key people at Quanta Therapeutics.
Quanta Therapeutics has raised $111.0M in total across 2 funding rounds.
Quanta Therapeutics develops allosteric small molecules to inhibit RAS mutations, including KRAS G12D and G12V, in difficult-to-treat cancers. The company utilizes a proprietary Second Harmonic Generation (SHG) platform, an optical technology detecting subtle protein conformational changes. This enables the discovery of small molecules precisely modulating signaling complexes, broadening therapeutic options.
Founded in 2018, Quanta Therapeutics arose from the insight that many RAS-driven cancers lacked effective treatment, existing inhibitors addressing only a narrow subset of mutations. A team of seasoned RAS biology leaders, medicinal chemists, and clinical development experts formed the company. Their combined scientific foundation, from pioneering RAS signaling research, guides their strategy.
Quanta Therapeutics targets patients with various RAS-driven cancers, such as pancreatic, colorectal, lung, and endometrial types. Its pipeline includes clinical-stage candidates for a wide KRAS mutation spectrum. The company's vision is to advance RAS therapy, delivering best-in-class oral medicines that expand the treatable landscape of RAS-mutated cancers.
Quanta Therapeutics has raised $111.0M in total across 2 funding rounds.
Quanta Therapeutics's investors include Lei Meng, KohFounders, Carol Gallagher, Omega Funds, Sofinnova Investments, SV Health Investors, The Column Group, venBio, Venrock, Versant Ventures, Vida Ventures, AbbVie Ventures.
Quanta Therapeutics has raised $111.0M across 2 funding rounds. Most recently, it raised $51.0M Series D in May 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2023 | $51M Series D | LEI Meng | KohFounders, Carol Gallagher, Omega Funds, Sofinnova Investments, SV Health Investors, The Column Group, VenBio Partners, Venrock, Versant Ventures, Vida Ventures, AbbVie Ventures, BVF Partners, Gc&h Investments, Longitude Capital, Surveyor Capital, WS Investment Company | Announced |
| Oct 1, 2021 | $60M Series C | Vida Ventures, Surveyor Capital | Carol Gallagher, Omega Funds, SV Health Investors, The Column Group, AbbVie Ventures, BVF Partners, Logos Capital, Longitude Capital, Sofinnova Investments | Announced |
Key people at Quanta Therapeutics.
# Quanta Therapeutics: A Biopharmaceutical Pioneer in RAS-Targeted Oncology
Quanta Therapeutics is not a technology company in the traditional sense—it is a biopharmaceutical company focused on developing novel cancer medicines that target previously undruggable RAS mutations.[1][2] While the company employs proprietary technology as a core tool, its primary mission is therapeutic drug development rather than technology commercialization.
Quanta develops allosteric small molecule inhibitors targeting KRAS mutations, which drive nearly one-quarter of all cancers.[2] The company addresses a critical gap in oncology: existing KRAS inhibitors target only the G12C mutation, which represents approximately 10% of KRAS-driven cancers.[2] Quanta's approach expands treatment options to previously difficult-to-treat cancers including pancreatic, colorectal, lung, and endometrial cancers by targeting KRAS G12D and G12V mutations through allosteric modulation.[2]
Quanta's pipeline includes multiple oral, small-molecule KRAS inhibitors in Phase 1 clinical development.[1][5] As of July 2025, the company advanced QTX3034 (a G12D-preferring multi-KRAS inhibitor) into dose expansion cohorts based on favorable safety and encouraging preliminary efficacy data, with evaluation ongoing both as monotherapy and in combination with cetuximab.[1] The company has raised $110 million across two funding rounds, with the most recent funding round totaling $50 million.[3]
Quanta operates at the intersection of two major oncology trends: the expansion of precision medicine beyond single-mutation targets and the growing recognition that allosteric modulation offers advantages over direct active-site inhibition. The company's work directly addresses the "RAS problem"—the historical difficulty in drugging RAS mutations that have long been considered undruggable. By applying protein conformation detection technology to oncology, Quanta exemplifies how specialized biotech platforms can unlock new therapeutic possibilities in mature disease areas, potentially influencing how the broader industry approaches previously intractable protein targets.
Quanta's trajectory depends on Phase 1 clinical data maturation and successful progression to Phase 2 trials. According to industry benchmarks, Phase 1 drugs for lung cancer have a 78% phase transition success rate.[4] The company's differentiated approach to KRAS targeting—focusing on mutations beyond G12C—positions it to capture a significantly larger patient population than existing therapies if clinical efficacy is demonstrated. As KRAS-driven cancers represent a substantial market opportunity, successful advancement of its pipeline could establish Quanta as a meaningful player in next-generation RAS therapeutics, potentially influencing treatment paradigms across multiple cancer types.
